Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and
efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or
intolerant to standard-of-care therapy that exhibit wild-type (WT) TP53 and MDM2 copy number
(CN) ≥ 12 using prespecified biomarker criteria.